Amneal Pharmaceuticals, Company Insiders
AMRX Stock | USD 8.27 0.08 0.96% |
Amneal Pharmaceuticals, employs about 7.8 K people. The company is managed by 27 executives with a total tenure of roughly 74 years, averaging almost 2.0 years of service per executive, having 290.74 employees per reported executive. Break down of Amneal Pharmaceuticals,'s management performance can provide insight into the company performance.
Chintu Patel CEO Co-Chief Executive Officer, Co-Founder, Director |
Chirag Patel CEO President, Co-Chief Executive Officer, Co-Founder, Director |
Amneal |
Amneal Pharmaceuticals,'s Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Amneal Pharmaceuticals,'s future performance. Based on our forecasts, it is anticipated that Amneal will maintain a workforce of slightly above 7850 employees by January 2025.Amneal Pharmaceuticals, Management Team Effectiveness
The company has return on total asset (ROA) of 0.0594 % which means that it generated a profit of $0.0594 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8577) %, meaning that it created substantial loss on money invested by shareholders. Amneal Pharmaceuticals,'s management efficiency ratios could be used to measure how well Amneal Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.12 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.04). At this time, Amneal Pharmaceuticals,'s Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 933.3 M in 2024, whereas Total Assets are likely to drop slightly above 3.2 B in 2024.Common Stock Shares Outstanding is likely to drop to about 151.5 M in 2024. Net Loss is likely to rise to about (111.1 M) in 2024
Amneal Pharmaceuticals, Workforce Comparison
Amneal Pharmaceuticals, Class is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 24,409. Amneal Pharmaceuticals, totals roughly 7,850 in number of employees claiming about 32% of equities under Health Care industry.
Amneal Pharmaceuticals, Profit Margins
The company has Profit Margin (PM) of (0.07) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.47 | 0.3428 |
|
|
Amneal Pharmaceuticals, Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amneal Pharmaceuticals, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amneal Pharmaceuticals,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Amneal Pharmaceuticals, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 1.6364 | 18 | 11 | 1,097,083 | 756,658 |
2024-03-01 | 0.931 | 27 | 29 | 7,438,825 | 34,294,566 |
2023-12-01 | 1.0 | 5 | 5 | 144,003,290 | 144,003,290 |
2023-09-01 | 0.5 | 1 | 2 | 54,949 | 84,251 |
2023-06-01 | 1.8 | 18 | 10 | 1,414,828 | 707,741 |
2023-03-01 | 1.0476 | 22 | 21 | 4,180,485 | 547,267 |
2022-06-01 | 1.3571 | 19 | 14 | 1,017,786 | 366,874 |
2022-03-01 | 0.8333 | 10 | 12 | 1,057,482 | 214,249 |
2021-12-01 | 2.0 | 2 | 1 | 3,123,298 | 2,000 |
2021-06-01 | 1.3571 | 19 | 14 | 742,466 | 463,249 |
2021-03-01 | 0.9 | 9 | 10 | 851,626 | 201,665 |
2020-12-01 | 1.0 | 3 | 3 | 22,566 | 22,566 |
2020-09-01 | 3.0 | 3 | 1 | 125,130 | 27,923 |
2020-06-01 | 1.8889 | 17 | 9 | 484,959 | 63,072 |
2020-03-01 | 1.75 | 14 | 8 | 1,632,158 | 98,193 |
2019-12-01 | 1.625 | 13 | 8 | 13,854,248 | 26,633,597 |
2019-06-01 | 1.625 | 26 | 16 | 356,349 | 340,223 |
2019-03-01 | 4.0 | 12 | 3 | 1,198,545 | 68,345 |
2018-09-01 | 2.0 | 4 | 2 | 61,020,567 | 61,698 |
Amneal Pharmaceuticals, Notable Stakeholders
An Amneal Pharmaceuticals, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Amneal Pharmaceuticals, often face trade-offs trying to please all of them. Amneal Pharmaceuticals,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Amneal Pharmaceuticals,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Chintu Patel | Co-Chief Executive Officer, Co-Founder, Director | Profile | |
Chintu RPh | CoCEO CoFounder | Profile | |
Chirag Patel | President, Co-Chief Executive Officer, Co-Founder, Director | Profile | |
Paul Meister | Independent Chairman of the Board | Profile | |
Sanjay Jain | President Operations | Profile | |
Anastasios Konidaris | Chief Financial Officer, Executive Vice President | Profile | |
Nikita Shah | Chief Human Resource Officer, Executive Vice President, Strategic Planning Officer | Profile | |
Andrew Boyer | Executive Vice President, Chief Commercial Officer - Generics | Profile | |
Stephen Manzano | Senior Vice President, General Counsel and Corporate Secretary | Profile | |
Joseph Greer | Senior Vice President - Global Quality Management | Profile | |
Joseph Todisco | Executive Vice President, Chief Commercial Officer - Specialty | Profile | |
Gautam Patel | Director | Profile | |
Ted Nark | Independent Director | Profile | |
Emily Alva | Independent Director | Profile | |
John Kiely | Independent Director | Profile | |
Pranav Mehta | Senior Management | Profile | |
Jason Esq | Chief VP | Profile | |
Jeffrey George | Independent Director | Profile | |
Shlomo Yanai | Independent Director | Profile | |
Nikunj Patel | Head Ltd | Profile | |
Gregory Sgammato | Senior Development | Profile | |
Sanjiv Patel | VP Operations | Profile | |
Anthony DiMeo | Director Relations | Profile | |
Jason Daly | Senior Vice President Chief Legal Officer and Corporate Secretary | Profile | |
Apurva Saraf | Senior Vice President - Corporate Development | Profile | |
RPh RPh | CoCEO CoFounder | Profile | |
J Buchi | Independent Director | Profile |
About Amneal Pharmaceuticals, Management Performance
The success or failure of an entity such as Amneal Pharmaceuticals, often depends on how effective the management is. Amneal Pharmaceuticals, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Amneal management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Amneal management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.04) | (0.04) | |
Return On Capital Employed | 0.08 | 0.12 | |
Return On Assets | (0.02) | (0.02) | |
Return On Equity | (4.25) | (4.03) |
Please note, the imprecision that can be found in Amneal Pharmaceuticals,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Amneal Pharmaceuticals, Class. Check Amneal Pharmaceuticals,'s Beneish M Score to see the likelihood of Amneal Pharmaceuticals,'s management manipulating its earnings.
Amneal Pharmaceuticals, Workforce Analysis
Traditionally, organizations such as Amneal Pharmaceuticals, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Amneal Pharmaceuticals, within its industry.Amneal Pharmaceuticals, Manpower Efficiency
Return on Amneal Pharmaceuticals, Manpower
Revenue Per Employee | 304.9K | |
Revenue Per Executive | 88.7M | |
Net Loss Per Employee | 6.2K | |
Net Loss Per Executive | 1.8M | |
Working Capital Per Employee | 67.7K | |
Working Capital Per Executive | 19.7M |
Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.